Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Wolin on the Safety of Lutathera in Advanced NETs

October 2nd 2020

Edward Wolin, MD, discusses the safety profile of 177Lu-dotatate in patients with advanced neuroendocrine tumors.

Telotristat/Lutathera Combo Could Improve Outcomes in Well-Differentiated NETs

October 2nd 2020

Investigators are evaluating the combination of telotristat ethyl and Lutathera with a goal to improve progression-free survival in patients with well-differentiated neuroendocrine tumors in a randomized, phase 2 study that was highlighted during the 2020 NANETs Virtual Symposium.

Long-Term Toxicity Data Confirm the Tolerability of Lutathera in NETs

October 2nd 2020

Longer-term data demonstrated that treatment with the radiopharmaceutical Lutathera continued to show low rates of toxicity among patients with somatostatin receptor–positive neuroendocrine tumors.

Pursuing Improved Survival With KRAS, PARP Inhibitors and Metabolic Agents in Pancreatic Cancer

October 2nd 2020

Although chemotherapy remains the benchmark for drug development in pancreatic cancer, signals seen with selective KRAS-targeted agents, PARP inhibitors, and metabolic agents suggest that novel approaches do have the ability to prolong survival in the advanced setting.

Dr. Zalcberg on the Management of Patients With GIST

October 1st 2020

John Zalcberg, PhD, OAM, discusses the management of patients with gastrointestinal stromal tumor.

Deirdre J. Cohen, MD, MS, Appointed as Director of Gastrointestinal Oncology Program of Mount Sinai Health System

September 29th 2020

Deirdre J. Cohen, MD, MS, an expert in pancreatic and other gastrointestinal cancers as well as an accomplished clinical trial leader, has joined Mount Sinai Health System as Director of the Gastrointestinal Oncology Program and Medical Director of the Cancer Clinical Trials Office at The Tisch Cancer Institute.

Injectable Sintilimab/Bevacizumab Biosimilar Combo Improves Survival in Frontline HCC

September 28th 2020

Frontline sintilimab injection in combination with bevacizumab biosimilar injection resulted in a statistically significant improvement in progression-free survival and overall survival compared with sorafenib in patients with advanced hepatocellular carcinoma.

Today’s Molecular Profiling Efforts Will Define the New Decade of GI Cancer Management

September 26th 2020

Over the past decade in gastrointestinal cancer treatment, the acknowledgement that cancer is heterogeneous and likely polyclonal has prompted a shift from gene testing for some patients, to many patients.

Trastuzumab Deruxtecan Approved in Japan for HER2+ Metastatic Gastric Cancer

September 26th 2020

The Japanese Ministry of Health, Labor, and Welfare has approved the antibody-drug conjugate trastuzumab deruxtecan for the treatment of patients with HER2-positive unresectable advanced or recurrent gastric cancer that has progressed following chemotherapy.

FDA Grants Fast Track Status to DKN-01 for Gastric and GEJ Cancer

September 25th 2020

The FDA has granted a fast track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors have high DKK1 expression, who have progressed on or after a fluoropyrimidine- and platinum-containing chemotherapy, and HER2/neu targeted therapy, if appropriate.

Investigators Untangle Emerging Strategies in Gastric Cancer

September 23rd 2020

Findings from clinical trials evaluating HER2-directed and immunotherapeutic approaches for treating patients with gastric cancer are among recent data attracting interest from experts in the gastrointestinal cancer field.

Ivosidenib Shows Modest OS Trend in IDH1+ Cholangiocarcinoma

September 22nd 2020

Ivosidenib demonstrated a consistent trend toward improved overall survival compared with placebo in treatment-naïve patients with IDH1-positive cholangiocarcinoma, although the benefit was not determined to be statistically significant.

Nivolumab/Chemo Improves PFS, Elicits Durable Responses in Gastric/GEJ Cancers

September 21st 2020

The addition of nivolumab to chemotherapy resulted in a statistically significant improvement in progression-free survival and elicited higher overall response rates in patients with previously untreated advanced or recurrent gastric and gastroesophageal junction cancer.

Dr. Kelly on the Rationale for the CheckMate-577 Trial in Esophageal/GEJ Cancer

September 21st 2020

Ronan J. Kelly, MD, MBA, discusses the rationale to conduct the phase 3 CheckMate-577 study in esophageal or gastroesophageal junction cancer.

Frontline Nivolumab/Chemo Combo Improves Survival in Gastric/GEJ Cancer and Esophageal Adenocarcinoma

September 21st 2020

First-line treatment with the combination of nivolumab and chemotherapy led to a statistically significant survival benefit among previously untreated patients with PD-L1–positive advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma versus chemotherapy alone.

Durvalumab/Tremelimumab Shows Modest Activity in Advanced NETs With GEP and Lung Origins

September 21st 2020

The addition of durvalumab to tremelimumab showed modest activity in patients with advanced neuroendocrine tumors of gastroenteropancreatic and lung origins.

Pembrolizumab/Chemo Combo Represents New Frontline Standard in Advanced Esophageal Cancer

September 21st 2020

Frontline pembrolizumab plus chemotherapy significantly improved overall survival, progression-free survival, and objective response rates compared with chemotherapy alone in patients with locally advanced unresectable or metastatic esophageal cancer.

Lenvatinib/Pembrolizumab Combo Shows Antitumor Activity in Previously Treated Advanced Solid Tumors

September 20th 2020

Lenvatinib plus pembrolizumab showed early antitumor activity and tolerability in previously treated patients with advanced solid tumors.

Surufatinib Improves PFS in Advanced Pancreatic NETs

September 20th 2020

The novel VEGFR, FGFR, and CSF-1R inhibitor surufatinib yielded a statistically significant and clinically meaningful progression-free survival benefit compared with placebo in patients with advanced pancreatic neuroendocrine tumors.

HAIC Shows Better Efficacy and Safety in Unresectable HCC Versus Standard of Care

September 20th 2020

Overall survival was significantly improved in patients who received hepatic arterial infusion chemotherapy with oxaliplatin, fluorouracil, and leucovorin compared with transarterial chemoembolization.